| Sera from patients with diabetes do not alter the effect of mammalian target of rapamycin inhibition on smooth muscle cell proliferation. | |
| | |
MedLine Citation:
|
PMID: 19129735 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Clinical studies of drug-eluting stents delivering the mammalian target of rapamycin (mTOR) inhibitor, rapamycin (Sirolimus), have demonstrated a reduced efficacy for these devices in patients with diabetes, which suggests that the mTOR pathway may cease to be dominant in mediating the vascular response to injury under diabetic conditions. We hypothesized that changes in serum composition accompanying diabetes may reduce the role of mTOR in mediating the vascular response to injury. We measured the ability of a median dose of rapamycin (10 nM) to inhibit the proliferation of human coronary artery smooth muscle cells (huCASMCs) stimulated with serum obtained from donors with diabetes (n = 14) and without diabetes (n = 16). In an additional analysis, we compared the effects of rapamycin on huCASMCs stimulated with the serum of donors with metabolic syndrome (n = 15) versus those without (n = 7). There was no difference in the effect of rapamycin on huCASMC proliferation after stimulation with serum from either donors with diabetes or donors with metabolic syndrome compared with the respective controls. We conclude that the changes in the serum composition common to diabetes and metabolic syndrome are insufficient to diminish the role of mTOR in the progression of cardiovascular disease. |
| | |
Authors:
|
Stephanie C Moss; Daniel Lightell; Richard E Deichmann; T Cooper Woods |
Related Documents
:
|
8154515 - Diabetes mellitus: a disease of abnormal cellular calcium metabolism? 10332565 - Androgens and abdominal obesity. 9642645 - Non-insulin dependent diabetes mellitus in a prepubertal child with prader-willi syndrome. 19421055 - Dissecting the role of insulin resistance in the metabolic syndrome. 7018265 - Role of follicle wall in meiosis reinitiation induced by insulin in rana pipiens oocytes. 20067965 - A1c for screening and diagnosis of type 2 diabetes in routine clinical practice. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of cardiovascular pharmacology Volume: 53 ISSN: 1533-4023 ISO Abbreviation: J. Cardiovasc. Pharmacol. Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2010-06-21 Completed Date: 2010-09-20 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 7902492 Medline TA: J Cardiovasc Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 86-9 Citation Subset: IM |
Affiliation:
|
Ochsner Clinic Foundation, New Orleans, LA 70121, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Animals Cell Proliferation / drug effects* Diabetes Mellitus / metabolism Diabetes Mellitus, Type 2 / metabolism Drug-Eluting Stents Female Humans Male Mammals / metabolism Middle Aged Muscle, Smooth / metabolism Myocytes, Smooth Muscle / drug effects*, metabolism Sirolimus / metabolism, pharmacology* |
| Grant Support | |
ID/Acronym/Agency:
|
P20 RR018766-066844/RR/NCRR NIH HHS; P20RR018766-06/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
53123-88-9/Sirolimus |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Fo...
Next Document: Hemodynamic and Cardiac Neurotransmitter-releasing Effects in Conscious Dogs of Attention- and Wake-...